BrightSpring Health Services

Overview

BrightSpring Health Services (NASDAQ: BTSG) is a public care-at-home and pharmacy services platform whose manufacturer-facing relevance sits inside five pharmacy assets: Onco360 (oncology specialty pharmacy), CareMed (rare and orphan disease dispensing), ConnectMed360 (patient support, reporting, and distribution services), Amerita (home and alternate-site infusion), and PharMerica (long-term-care pharmacy). The buyer question is not BrightSpring’s overall healthcare breadth; it is whether the therapy needs a coordinated specialty-pharmacy, hub, infusion, LTC, or care-at-home path that one platform can manage across multiple patient settings.

BrightSpring is not a narrow LDD-only specialty pharmacy and not a single-brand hub. It is a multi-unit specialty platform: Onco360 and CareMed cover SP dispensing lanes, ConnectMed360 adds manufacturer-facing patient support and reporting, Amerita brings infusion site-of-care, and PharMerica adds institutional reach for senior, skilled-nursing, hospice, and post-acute populations a conventional SP cannot replicate.

Operating Unit Map

Unit	Launch-team relevance	Diligence focus
Onco360	Oncology specialty pharmacy channel for oral, injectable, and infused cancer therapies.	Confirm LDD participation, payer network position, REMS scope, oncology pharmacist model, and manufacturer data cadence.
CareMed	Rare and orphan disease specialty-pharmacy support.	Validate disease-team depth, benefits / PA workflows, patient-services handoffs, and rare-disease reporting.
ConnectMed360	Patient support, access, data / technology, and distribution services for cancer, rare, and complex therapies.	Confirm hub scope, patient-status / dispense / adherence reporting, free-drug / bridge / quick-start distribution, and portal ownership.
Amerita	Home and alternate-site infusion for therapies that need administration support.	Confirm geography, nursing model, referral intake speed, buy-and-bill versus pharmacy-benefit handling, and escalation coverage.
PharMerica	LTC pharmacy reach across skilled-nursing and hospice settings.	Validate whether the therapy has an institutional / senior-care access need and how reporting flows back to the brand team.
Provider Services	Home health, rehab therapy, hospice, and personal-care adjacency.	Treat as care-setting reach, not a substitute for a dedicated hub; define handoffs clearly.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, BrightSpring Health Services is evaluated as a public care-at-home and pharmacy services platform whose manufacturer-facing relevance sits inside Onco360, CareMed, ConnectMed360, Amerita, and PharMerica.

Capability	Buyer should compare	BrightSpring Health Services readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Onco360 and CareMed give BrightSpring focused specialty-pharmacy lanes in oncology and rare disease.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Unit-specific. ConnectMed360 adds explicit BI / BV / PA / appeal, affordability, bridge, quick-start, and patient-assistance workflows; specify the unit-by-unit support model in the RFP.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Strong fit where pharmacy and care-at-home overlap. BrightSpring’s platform is built around complex senior and specialty populations, but the protocol should be therapy-specific.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Relevant for oncology, rare disease, biologics, and infusion. Confirm which requirements are handled by Onco360, CareMed, Amerita, or partners.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Important diligence item. ConnectMed360 describes pharma portals, de-identified transaction data, automated patient-status / dispense / adherence reporting, and Compass provider reporting; require a single reporting owner across units.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Differentiated when Amerita is relevant. The platform can combine dispensing and infusion support for products that need more than pharmacy shipment.

Buyer Fit

• Buyer trigger: A brand whose patient journey crosses settings - specialty dispense followed by home or ambulatory infusion, a rare-disease therapy with high-touch patient services, an oncology therapy needing tight prescriber coordination, or a product with meaningful institutional / post-acute reach.
• Best-fit buyers: Oncology, rare-disease, immunology, and infusion-adjacent launch teams who want one contracting counterparty for SP + hub / patient support + infusion + LTC reach instead of stitching together several vendors.
• Less ideal fit: Brands needing only a narrow digital hub, a pure payer-access consulting engagement, or a pharmacy partner with PBM-owned formulary leverage; focused hub vendors, PBM-owned SPs, and pure-play infusion operators are the comparison set there.
• Commercial fit: Pricing is undisclosed; expect a unit-by-unit RFP scope with a single reporting owner across Onco360, CareMed, Amerita, and PharMerica touchpoints.
• Profile signal: Public BTSG financials with raised 2026 guidance, two reportable segments (Pharmacy Solutions, Provider Services), and the March 2026 ResCare Community Living divestiture narrowing the story around pharmacy and care-at-home growth markets.
• Integration diligence: Confirm which operating unit holds the manufacturer contract, how ConnectMed360 data is consolidated with dispensing or infusion data, where REMS / cold chain / CGT requirements sit, and how duplicate patient outreach across units is prevented.

Differentiators

• Onco360 oncology focus: BrightSpring can bring a specialty-pharmacy lane built specifically for oncology prescribing, counseling, and access workflows.
• CareMed rare-disease lane: CareMed gives the platform a rare / orphan disease channel that can sit alongside oncology rather than forcing all specialty products through a broad generalist model.
• ConnectMed360 hub layer: ConnectMed360 adds patient support, access, reporting, non-commercial dispensing, bridge / quick-start distribution, portals, SMS, e-enrollment, e-prescribing, e-consent, and e-signature workflows.
• Amerita infusion adjacency: Amerita lets launch teams design a combined specialty pharmacy plus home / alternate-site infusion model when the product requires administration support.
• PharMerica institutional reach: PharMerica adds a long-term-care pharmacy route that matters for products with senior, skilled-nursing, or hospice exposure.
• Public, scaled platform: BrightSpring’s public-company profile and multi-state operating scale make it easier to diligence than smaller private specialty-pharmacy platforms, but buyers still need operating-unit-level contracting clarity.

RFP Questions

• Which BrightSpring operating unit will own the manufacturer contract, and which units will touch the patient journey?
• Which ConnectMed360 patient-services, data / technology, and distribution modules are in scope, and which are handled by Onco360, CareMed, Amerita, PharMerica, or another partner?
• What LDD, payer, prescriber, health-system, and infusion channels can BrightSpring access for this specific product?
• How will Onco360 / CareMed specialty-pharmacy data be combined with Amerita infusion or PharMerica institutional data if more than one unit is involved?
• Which services are performed internally versus handed to an external hub, copay vendor, nursing vendor, or logistics partner?
• What are the launch-specific service levels for benefit investigation, prior authorization, first fill, abandonment recovery, refill outreach, and adverse-event escalation?
• How can BrightSpring support the therapy’s REMS, cold-chain, clinical documentation, site-of-care, and reporting requirements without creating duplicate patient outreach?

Recent Activity

• 2026: BrightSpring’s current pharmacy-services materials list ConnectMed360 as a flagship pharmacy brand and describe patient support, data / technology, and distribution services for cancer, rare, and complex therapies.
• Q1 2026: BrightSpring reported strong first-quarter results and raised full-year 2026 guidance.
• March 2026: BrightSpring completed the sale of ResCare Community Living to Sevita, narrowing the public story around pharmacy and provider-services growth markets.
• 2026: BrightSpring continued positioning Pharmacy Solutions and Provider Services as the two reportable segments buyers should understand before mapping a manufacturer program to the platform.